

MONONUCLEAR RUTHENIUM (II) COMPOUNDS AS NOVEL CYTOTOXIC AGENTS

Shyam Sunder A^{1*}, Satyavati D², Sreekanth T³, Ramakrishna S⁴ Lakshma Nayak V⁴,
Vishnuvardhan MVPS⁴

¹Department of Pharm.D, Balaji Institute of Pharmaceutical Sciences,
Laknepally, Narsampet, Warangal, Telangana State, India.

²Director, Brilliant Grammar School Educational Society's Group of Institutions, Integrated Campus,
Engineering and Pharmacy, Abdullapurmet, Rangareddy, Hyderabad, Telangana State, India

³CDTS, Fundação Oswaldo Cruz - Ministério da Saúde, Av. Brasil 4036 - Prédio da Expansão, 8^o Andar -
Sala 814, Manginhos, 21040-361 - Rio de Janeiro - RJ – Brasil.

⁴Division of Pharmacology, Indian Institute of Chemical Technology, Hyderabad, Telangana State, India.

*Corresponding Author Email: shyamar9@gmail.com

ABSTRACT

The present study was aimed to evaluate in vitro anticancer activity of newly synthesized two mononuclear Ru(II) compounds of the type $[Ru(A)_2(B)]Cl_2$ where A=1,10-phenanthroline B=2-NO₂-PTSZ (Compound R₁), 2-OH-PTSZ (Compound R₂) against various cancer cell lines using MTT assay. A panel of cancer cell lines: A549 (lung cancer), HT-29 (colon cancer), PC-3 (prostate cancer) and B-16 (mouse melanoma) were studied for cytotoxicity using MTT assay. The results revealed that the test Ru(II) compounds were able to inhibit the cancer cell growth in a dose dependent manner. The compound R₂ showed significant cytotoxic activity with IC₅₀ values ranging from 16 to 38 µg/ml against all the above cell lines, whereas the compound R₁ displayed the IC₅₀ values ranging from 74 to 127 µg/ml and was found to be inactive against HT29 cell lines. The results concluded that the compound R₂ appears to be better cytotoxic agent than R₁.

KEY WORDS

Carcinogenicity, Cytotoxicity, MTT, PTSZ, Ruthenium compounds.

1. INTRODUCTION

Cancer is a generic term in which abnormal cells divide mitotically without control and it includes a large group of diseases that can affect any part of the body. In today's world cancer is a leading cause of death worldwide, accounting for 8.2 million deaths in 2012. It is expected that annual cancer cases will rise from 14 million in 2012 to 2022 within the next 2 decades (World Cancer Report-2014)

In recent years, metal-based therapeutic drugs have been used as anticancer agents [1] for

example, cisplatin is considered to be one of the most effective and widely used metal based anticancer drugs [2]. However, the efficacy of cisplatin is reduced by increasing tumour resistance and high toxicity [3,4]. These drawbacks have started interest towards the design and evaluation of transition metallic complexes, especially the ruthenium compounds for their reduced toxicity to host cells at therapeutic doses [5].

One particular set of Schiff bases as chelating agents that have been studied over the past decade is the thiosemicarbazones (TSCs). TSCs are

potent inhibitors of the enzyme ribonucleotide reductase and are capable of impairing the DNA synthesis and repair [6]. The biological properties of the ligands can be modified and mostly enhanced by linkage to metal ions [7]. In this view, we synthesized some mononuclear Ruthenium(II) compounds of the type $[Ru(A)_2(B)]Cl_2$ where A=1,10-phenanthroline B=2-NO₂-phenyl thiosemicarbazone (compound R₁), 2-OH-phenyl thiosemicarbazone (compound R₂) and were evaluated for cytotoxicity against various cancer cell lines.

Several studies have shown that tumor growth can cause antioxidant disturbances in certain tissues of the tumor hosts [8]. Cancer cells can generate large amounts of hydrogen peroxide free radicals, which may have the ability to mutate, damage normal tissues and invade other tissues. This suggests that there was a direct correlation between changes in the rate of cancer cell proliferation and the antioxidant defensive machinery [9]. In view, recently we have reported the above mononuclear Ru(II) complexes for *in vitro* free radical scavenging activity and the

compounds possess an excellent antioxidant activity toward selected free radical donors [10]. On this basis we have evaluated the above test compounds for cytotoxic activity using different cancer cell lines, A549 (lung cancer), HT-29 (colon cancer), PC-3 (prostate cancer) and B-16 (mouse melanoma) and the results concluded that the compounds possess significant inhibition of proliferation of cancer cells. By inhibiting the proliferation, we can able to suppress the free radical generation by tumor cells.


2. MATERIALS AND METHODS

2.1. Chemicals:

Dulbecco's modified eagle's medium (DMEM), Fetal bovine serum (FBS), penicillin, amphotericin B, and streptomycin were purchase from Himedia (Mumbai, India). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) purchased from Sigma Chemical Company (St. Louis, MO, USA).


2.2. Structures of test compounds:

The structures of test ruthenium compounds (R₁ and R₂) were shown below:



Compound R₁

$Ru(1,10\text{-phenanthroline})_2(2\text{-nitro-Phenyl thiosemicarbazone}) Cl_2$



Compound R₂

$Ru(1,10\text{-phenanthroline})_2(2\text{-hydroxy-phenyl thiosemicarbazone}) Cl_2$

2.3. *In vitro* cytotoxicity assay:

Cytotoxicity of the ruthenium compounds were determined using MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) reduction assay [11] and is suitable for measuring cell

proliferation, cell viability or cytotoxicity. 1×10^4 cells/well were seeded in 100 μ l DMEM supplemented with 10% FBS in each well of 96-well micro culture plates and incubated for 24 h at 37°C in a CO₂ incubator. Ruthenium

compounds diluted to the desired concentrations in culture medium and incubated with the cells. After 48 h of incubation, media were removed and to each well 10 μ l of MTT (5 mg/mL) was added and the plates were further incubated for 4 h. Supernatant from each well was carefully removed, formazan crystals were dissolved in 100 μ l of DMSO and absorbance at 540 nm wavelength was recorded. The absorbance of the test was compared with that of DMSO control to get the %inhibition and then IC_{50} values were calculated and compared with standard, Doxorubicin.

3. RESULTS

The synthesized compounds, R_1 and R_2 were evaluated for their *in vitro* anti cancer activity

against a panel of four cancer cell lines, A549 (Lung cancer), HT-29 (Colon cancer), PC-3 (Prostate cancer) and B-16 (Mouse melanoma) along with standard compound, Doxorubicin by employing MTT assay. *In vitro* cytotoxic activity of ruthenium compounds revealed that these compounds inhibited the growth of various cell lines in dose dependent manner. In this assay, compound R_2 showed a significant anti cancer activity with the IC_{50} values, 38.01, 16.21, 20.89 and 32.35 μ g in lung, colon, prostate and melanoma cancer cell lines respectively. However, compound R_1 showed a moderate activity with IC_{50} values of 79.4 against A549, 127.9 against PC-3, 74.6 μ g against B-16 and was found to be inactive against HT-29 cell lines (Table 1 & Figures 1-4).

Table 1. Inhibitory effect of R_1 & R_2 complexes on proliferation of A549, HT-29, PC-3 & B-16 cell lines

Compounds	IC_{50} (μ g/ml)			
	A549	HT-29	PC-3	B-16
R_1	79.4 $\pm$ 1.05	Not active	127.9 $\pm$ 3.54	74.6 $\pm$ 1.98
R_2	38.01 $\pm$ 0.97	16.21 $\pm$ 1.08	20.89 $\pm$ 2.89	32.35 $\pm$ 3.16
Doxorubicin	1.81 $\pm$ 1.56	1.23 $\pm$ 0.99	1.31 $\pm$ 0.09	1.94 $\pm$ 2.99

Figure 1. Cytotoxicity of ruthenium complexes on A549 cell lines




Figure 2. Cytotoxicity of ruthenium complexes on HT-29 cell lines




Figure 3. Cytotoxicity of ruthenium complexes on PC-3 cell lines





Figure 4. Cytotoxicity of ruthenium complexes on B-16 cell lines



4. DISCUSSION

Metal and metal ions are showing a good impact on cellular processes [12], such as they influence not only natural processes like cell division and gene expression but also toxicity, carcinogenicity and antitumor chemistry [13]. Among the various transition metallic complexes that have been investigated, ruthenium compounds have placed as promising one [14] because of proposed mechanisms such as “activation by reduction” and “transferrin-targeted delivery” accounted for the excellent cytotoxicity and low general toxicity of ruthenium complexes [15].

Research on drugs based on ruthenium complexes is a fast developing field in medicine, especially in development of chemotherapeutic agents with minimal side effects and immunity to acquisition of drug resistance [16]. Many of biological properties have been attributed to ruthenium complexes, for example, antitumor activity [17-24], antioxidant activity [25], antinociceptive [26,27], antitubercular activity [28], antimicrobial & antimalarial activity [29] and immunomodulatory activity [30].

Successful completion of phase 1 trials of two ruthenium(III)-based compounds, namely Imidazolium [trans-tetrachloro (1H-imidazole) (S-dimethylsulfoxide) ruthenate(III)] (NAMI-A) [31,32] and Indazolium [trans-tetrachlorobis (1H-indazole) ruthenate(III)] (KP1019) [33,34] as antimetastatic agents can encouraged for the synthesis of above ruthenium compounds and were evaluated for anticancer activity *in vitro*. The test ruthenium compounds have shown a dose dependant inhibition of cancer cell growth, it may be due to the antioxidant activity of test compounds. Of these two ruthenium compounds, R₂ was found to be better cytotoxic properties than R₁. By comparing the IC₅₀ values of ruthenium complexes with the doxorubicin, it was found that the test compounds were less potent than the standard drug. It may be due to lack of selectivity or insufficient dose to that particular cell line. Hence, further *in vitro* work is needed to know the selectivity of ruthenium compounds against other cell lines.

Conflict of interest: we have no conflict of interest.

REFERENCES

- [1] Roat-Malone RM. Metals in Medicine. In: Bioinorganic chemistry: A short course, John Wiley and Sons, Inc, Hoboken, NJ, USA, 265–335, (2003).
- [2] Hannon MJ., Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biology. *Pure Appl Chem*, 79: 2243–2261, (2007).
- [3] Clarke MJ., Zhu F., Frasca DR., Non-platinum chemotherapeutic metallopharmaceuticals. *Chem Rev*, 99: 2511–2534, (1999).
- [4] Agarwal R., Kaye SB., Ovarian cancer: strategies for overcoming resistance to chemotherapy. *Nat Rev Canc*, 3: 502–516, (2003).
- [5] Novakova O., Brabec V., DNA binding mode of Ruthenium complexes and relationship to tumour cell toxicity. *Drug Res Updates*, 9: 111–222, (2006).
- [6] Kovala-Demertzi D., Demertzis MA., Miller JR., Frampton CS., Jasinski JP., West DX., Structure of bis(2-acetylpyridine 3-hexamethyleneiminylthiosemicarbazonato) palladium(II), a potential antitumor complex. *J Inorg Biochem*, 92: 137–140, (2002).
- [7] West DX., Liberta AE., Padhye SB., Chikate RC., Sonawane PB., Kumbhar AS., Yerande RG., Thiosemicarbazone complexes of copper (II): structural and biological studies. *Coord Chem Rev*, 123: 49–71, (1993).
- [8] Badr El-Din NK., Protective role of sanumgerman against γ -irradiation-induced oxidative stress in Ehrlich carcinoma-bearing mice. *Nutri Res*, 24: 271–291, (2004).
- [9] Gupta M., Mazumder UK., Ramanathan SK., Siva Kumar T., Antitumor activity and antioxidant role of Bauhinia racemosa against Ehrlich ascites carcinoma in Swiss albino mice. *Acta Pharmacol Sin*, 25: 1070–1076, (2004).
- [10] Shyam Sunder A., Sreekanth T., Rajeshwar Y., Satyavati D., *In Vitro* Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium(II) Compounds. *Lett Drug Design Disc*, 9: 421–425, (2012).
- [11] Samanta K., Chakravarti B., Mishra JK., Dwivedi SKD., Nayak VL., Choudhry P., Bid HK., Konwar R., Chattopadhyay N., Panda G., Anti-tumor activity of a new series of benzoxazepine derivatives in breast cancer. *Bioorg Med Chem Lett*, 20: 283–287, (2010).
- [12] Reedijk J., Boumann E., Bioinorganic catalysis. New York: Dekker publishers; 1999.
- [13] Lippard PJ., Bioinorganic chemistry, a maturing Frontier. *Science*, 261: 699–700, (1993).
- [14] Bergamo A., Sava G., Ruthenium complexes can target determinants of tumour malignancy. *Dalton Trans*, 13: 1267–1272, (2007).
- [15] Ang WH., Dyson PJ., Classical and Non-Classical Ruthenium-Based Anticancer Drugs: Towards Targeted Chemotherapy. *Euro J Inorg Chem*, 20: 4003–4018, (2006).
- [16] Muggia F., Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer. *Gynecol Oncol*, 112: 275–281, (2009).
- [17] Keppler BK., Henn M., Juhl UM., Berger MR., Niebi R., Wagner FE., New ruthenium complexes for the treatment of cancer. *Prog Clin Biochem Med*, 10: 41–69, (1989).
- [18] Dougan SJ., Sadler PJ., The Design of Organometallic Ruthenium Arene Anticancer Agents. *CHIMIA Int J Chem*, 61: 704–715, (2007).
- [19] Dyson PJ., Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-clinical Development. *CHIMIA Int J Chem*, 61: 698–703, (2007).
- [20] Bruijninx PCA., Sadler PJ., Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design. *Adv Inorg Chem*, 61: 1–62, (2009).
- [21] Süss-Fink G., Arene ruthenium complexes as anticancer agents. *Dalton Trans*, 39: 1673–1688, (2010).
- [22] Govender P., Renfrew AK., Clavel CM., Dyson PJ., Therrien B., Smith GS., Antiproliferative activity of chelating N, O- and N, N-ruthenium (II) arene functionalised poly (propyleneimine) dendrimer scaffolds. *Dalton Trans*, 40: 1158–1167, (2011).
- [23] Tânia SM., Tiago JLS., Fernanda M., Paula Robalo M., Fernando A., Paulo JAM., Paulo JGM., Isabel S., Helena Garcia M., Synthesis of organometallic Ruthenium(II) complexes with strong activity against several human cancer cell lines. *J Inorg Biochem*, 114: 65–74, (2012).
- [24] Shyam Sunder A., Satyavati D., Sreekanth T., Rajeshwar Y., Krishna Prasad D., Novel Mononuclear Ruthenium(II) Compounds in Cancer Therapy. *Asian Pac J Can Prev*, 13: 3293–3298, (2012).
- [25] Paula MM., Pich CT., Petronilho F., Drei LB., Rudnicki M., DE Oliveira MR., Moreira JC., Henriques JA., Franco CV., Dal pizzol F., Antioxidant activity of new ruthenium compounds. *Redox Rep*, 10: 1–6, (2005).
- [26] Cristiano MP., Cardoso DC., da Silva Paula MM., Costa-Campos L., Antinociceptive effect of a ruthenium complex in mice. *Auton & Autac Pharmacol*, 28: 103–108, (2008).
- [27] Shyam Sunder A., Satyavati D., Sreekanth T., Rajeshwar Y., Balzarini J., Clercq ED., Antinociceptive and antitumor activity of novel synthetic mononuclear ruthenium (II) compounds. *J Res Med Sci*, 18: 215–221, (2013).

- [28] Hadda TB., Mehmetakkurt., Baba MF., Daoudi M., Bennani B., Kerbal A., Chohan ZH., Anti-tubercular Activity of Ruthenium(II) Complexes with Polypyridines. *J Enzy Inhib Med Chem*, 24: 457–463, (2009).
- [29] Shyam Sunder A., Satyavati D., Sreekanth T., Raja Narendra B., Rajeshwar Y., Rama Narsimha Reddy A., Antimicrobial and Antimalarial Activity of Novel Synthetic Mononuclear Ruthenium(II) Compounds. *J Chin Chem Soc*, 60: 153-159, (2013).
- [30] Newcomb JR., Rivnay B., Bastos CM., Ocain TD., Gordon K., Gregory P., Turci SM., Sterne KA., Jesson M., Krieger J., Jenson JC., Jones B., *In vitro* immunomodulatory activity of ruthenium complexes. *Inflamm Res*, 52: 263–271, (2003).
- [31] Sava G., Zorzet S., Turrin C., Vita F., Soranzo MR., Zabucci G., Cocchietto M., Bergamo A., DiGiovine S., Pezzoni G., Sartor L., Garbisa S., Dual Action of NAMI-A in Inhibition of Solid Tumor Metastasis: Selective Targeting of Metastatic Cells and Binding to Collagen. *Clin Cancer Res*, 9: 1898–1905, (2003).
- [32] Bacac M., Hotze ACG., van der Schilden K., Haasnoot JG., Pacor S., Alessio E., Sava G., Reedijk J., The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation. *J Inorg Biochem*, 98: 402–412, (2004).
- [33] Kapitzka S., Pongratz M., Jakupiec MA., Heffeter P., Berger W., Lackinger L., Keppler BK., Marian B., Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. *J Cancer Res Clin Oncol*, 131: 101–110, (2005).
- [34] Hartinger CG., Zorbas-Seifried S., Jakupiec MA., Kynast B., Zorbas H., Keppler BK., From bench to bedside—preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). *J Inorg Biochem*, 100: 891–904, (2006).



***Corresponding Author:**

shyamar9@gmail.com